Orthotopic Liver Transplant in a Patient Anticoagulated With Rivaroxaban: A Case Report

A A Pract. 2019 Jul 15;13(2):54-57. doi: 10.1213/XAA.0000000000000989.


Direct oral anticoagulants are approved for use in the United States and Europe and are increasingly used in chronic liver disease patients who have or are at risk of thrombotic events. While these drugs are clinically attractive because no monitoring is required, the risks and benefits in patients with hepatic or renal insufficiency who undergo surgery remain unclear. In this report, we describe the perioperative consequences, safety issues, and lessons learned from a patient undergoing an orthotopic liver transplant who was anticoagulated with rivaroxaban due to partial superior mesenteric vein thrombosis.

Publication types

  • Case Reports

MeSH terms

  • Factor Xa Inhibitors / administration & dosage*
  • Factor Xa Inhibitors / adverse effects
  • Female
  • Humans
  • Liver Cirrhosis / therapy*
  • Liver Transplantation
  • Mesenteric Ischemia / drug therapy
  • Middle Aged
  • Rivaroxaban / administration & dosage*
  • Rivaroxaban / adverse effects
  • Treatment Outcome


  • Factor Xa Inhibitors
  • Rivaroxaban